Reboxetine, sold under the brand name Edronax, is a drug marketed as a treatment for Major Depressive Disorderplugin-autotooltip__plain plugin-autotooltip_bigMajor Depressive Disorder

Major Depressive Disorder (MDD), also known simply as 'depression', is a mental disorder characterized by at least two weeks of pervasive low mood.

Current estimates are that severe depression affects around 2% of the global population at any given time, currently more than 150 million. The majority of cases don't appear to have an obvious personal and/or societal cause.,Attention-Deficit / Hyperactivity Disorder (ADHD)plugin-autotooltip__plain plugin-autotooltip_bigAttention-Deficit / Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD) is a neuro-developmental mental disorder. It's characterized by problems in paying attention, excessive activity, or difficulty in controlling behavior (typically not appropriate for a person's age). Symptoms usually begin at between six to twelve years of age, and, to be classified as ADHD must be present for more than six months and cause problems in at least two settings (e.g. school, home, or i…, and Panic Disorder - amongst others

It's thought to work as a norepinephrine reuptake inhibitor (NRI) - with special sensitivity for the norepinephrine transporter (NET).

Like Fluoxetineplugin-autotooltip__plain plugin-autotooltip_bigFluoxetine

Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) used in the treatment of Major Depressive Disorderand Obsessive-Compulsive disorder etc.. It's marketed under the trade names Prozac, Sarafem, Fontex and many others.

SSRIs are believed to act by inhibiting the re-uptake of the hormone serotonin, however, an exact mechanism of action has not yet been found.

Despite widespread efforts to understand the mechanisms of action of antidepressant drugs, the requisite changes in neural function that underlie their therapeutic effects remain unclear. […] However, taken together with previous findings that chronic administration of fluoxetine also results in enhanced activation of LC neurons to a stressor (Page and Abercrombie 1997), our present findings suggest a possible shared mechanistic link between two distinct classes of antidepressant compounds. The exact nature of the mechanism remains unclear but it is likely to rely on the sensitivity of the noradrenergic system to stressors.

Source : Nature Neuropsychopharmacology Vol. 27, pp. 237–247(2002)

Note regarding efficacy : A 2010 German study determined that Reboxetine works no better than a placeboplugin-autotooltip__plain plugin-autotooltip_bigPlacebo effect

Placebos are faux medications - typically lactose or microcrystalline cellulose - designed to act as inert, non-functional 'controls' in medical experiments. (There are also faux medical procedures, see section below)

From the beginnings of their use in research, experimenters had assumed that they could not possibly have any medical effect. But they are now being taken seriously as treatments, after it was discovered that totally inactive substances.